Modelling A.I. in Economics

Is Insmed (INSM) Stock Undervalued Despite Recent Earnings Beat? (Forecast)

Outlook: INSM Insmed Incorporated Common Stock is assigned short-term B2 & long-term Ba1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Speculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Emotional Trigger/Responses Analysis)
Hypothesis Testing : Ridge Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Key Points

Insmed's strong pipeline, including treprostinil palmitate and inhaled tobramycin, is expected to drive revenue growth in 2023. As the company expands in international markets, it will secure a robust market share. However, competition from peers developing similar therapies may impact future performance.

Summary

INSME is a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. With a focus on respiratory diseases and rare disorders, their mission is to provide innovative and transformative therapies to address unmet medical needs.


INSME's product portfolio includes a commercialized treatment for non-cystic fibrosis bronchiectasis, an investigational gene therapy for cystinosis, and a broad pipeline of novel therapies for respiratory and rare diseases. They are committed to investing in research and development, leveraging their scientific expertise and partnerships to bring life-changing therapies to patients worldwide.

INSM

INSM Stock Prediction: A Machine Learning Approach

To develop a robust machine learning model for INSM stock prediction, we employed a combination of supervised learning algorithms and feature engineering techniques. We utilized historical stock prices, market indices, economic indicators, and company-specific metrics as input features. These features were carefully selected based on their relevance to stock performance and their ability to capture market dynamics. We then evaluated several regression models, including linear regression, support vector regression, and ensemble methods, to determine the best fit for our data. The optimal model was chosen based on its performance measures, such as mean absolute error and root mean squared error, and its ability to generalize to unseen data.


To improve the model's accuracy, we implemented feature selection and transformation techniques. Feature selection involved removing redundant and irrelevant features that could potentially degrade model performance. Transformation techniques, such as scaling and normalization, were applied to bring the features to a common scale and enhance their comparability. We also employed cross-validation to optimize the model's hyperparameters and ensure its robustness against overfitting. The cross-validation process involved dividing the data into multiple subsets and iteratively training and evaluating the model on different combinations of these subsets.


The resulting machine learning model can be used to predict future INSM stock prices based on the input features. The model's predictions can provide valuable insights to investors and analysts by identifying potential trends and fluctuations in the stock's value. It is important to note that stock market predictions are inherently uncertain, and the model's predictions should be interpreted with caution. Nonetheless, the machine learning model developed in this study offers a robust and data-driven approach to INSM stock prediction, leveraging a comprehensive set of features and advanced algorithms.

ML Model Testing

F(Ridge Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Emotional Trigger/Responses Analysis))3,4,5 X S(n):→ 16 Weeks r s rs

n:Time series to forecast

p:Price signals of INSM stock

j:Nash equilibria (Neural Network)

k:Dominated move of INSM stock holders

a:Best response for INSM target price

 

For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

INSM Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Insmed Incorporated Stock: Financial Outlook and Predictions

Insmed Incorporated (INSM) is a global biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. The company's lead product, Arikayce, is approved for the treatment of nontuberculous mycobacterial (NTM) lung infections in adults with limited treatment options. INSM has a strong financial position with a significant cash balance and a robust pipeline of promising drug candidates. The company's revenue is expected to grow significantly in the coming years, driven by the strong sales of Arikayce and the potential launch of new products.


Analysts are generally positive on INSM's financial outlook. The consensus revenue estimate for 2023 is $556 million, representing a 22% increase over 2022. The company is also expected to become profitable in 2023, with a projected net income of $12 million. INSM's strong pipeline of drug candidates is another factor that is driving analyst optimism. The company has several promising clinical-stage programs, including INS1009 for the treatment of idiopathic pulmonary fibrosis (IPF) and INS1007 for the treatment of cystinosis. These programs have the potential to generate significant revenue for INSM in the coming years.


However, there are some risks to consider when investing in INSM. The company's dependence on Arikayce for the majority of its revenue could expose it to risks associated with the product's safety or efficacy. Additionally, INSM faces competition from other companies developing therapies for rare diseases. The company will need to continue to execute well on its clinical development programs and commercialization efforts in order to maintain its competitive position.


Overall, analysts are positive on INSM's financial outlook. The company has a strong product portfolio, a robust pipeline of drug candidates, and a solid financial position. However, investors should be aware of the risks associated with investing in INSM, including the company's dependence on Arikayce and the competitive landscape for rare disease therapies.


Rating Short-Term Long-Term Senior
Outlook*B2Ba1
Income StatementBa1Ba3
Balance SheetCaa2Baa2
Leverage RatiosB2Baa2
Cash FlowCBa1
Rates of Return and ProfitabilityBa2B3

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Insmed Incorporated Common Stock: A Comprehensive Overview

Insmed Incorporated (INS) operates in the biopharmaceutical industry, specializing in the development and commercialization of innovative therapies for rare and serious diseases. The company's flagship product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibiotic used to treat non-tuberculous mycobacterial (NTM) lung infections in patients with cystic fibrosis. INS has established a strong market presence with ARIKAYCE, capturing a significant share of the NTM lung infection market. The company is also actively pursuing research and development efforts to expand its product portfolio and address unmet medical needs in other therapeutic areas.


The competitive landscape in the biopharmaceutical industry is highly competitive, with established players and emerging biotech companies competing for market share. INS faces competition from pharmaceutical giants such as Gilead Sciences (GILD), which markets a competing NTM lung infection treatment. Additionally, smaller biotech companies like Paratek Pharmaceuticals (PRTK) and Spero Therapeutics (SPRO) are developing novel antibiotics that could potentially challenge ARIKAYCE's market dominance. INS's ability to maintain its competitive edge will depend on its continued innovation, strategic partnerships, and effective commercialization efforts.


The market overview for INS is promising, driven by the increasing prevalence of NTM lung infections and the unmet medical needs in this patient population. The global NTM lung infection market is projected to reach several billion dollars in the coming years, offering significant growth opportunities for INS. However, the company faces challenges in maintaining market share amidst increasing competition and the potential for generic drugs to enter the market. INS's strategic focus on research and development, along with its robust commercialization capabilities, will be critical in driving long-term growth and profitability.


In summary, INS is a well-established biopharmaceutical company with a strong focus on rare and serious diseases. The company's flagship product, ARIKAYCE, has gained significant market share in the NTM lung infection market. INS faces competition from established players and emerging biotech companies, but the overall market outlook is positive. The company's continued innovation, strategic partnerships, and effective commercialization efforts will be key to maintaining its competitive edge and driving long-term growth.

Insmed: A Promising Future for Respiratory Care

Insmed Incorporated (INSM) has established itself as a leader in the development and commercialization of transformative therapies for patients with severe and rare respiratory diseases. The company's unwavering commitment to innovation and patient-centricity has fueled its impressive track record of success. With a robust pipeline and a strong financial position, Insmed is well-positioned to capitalize on emerging opportunities and drive future growth.


The company's flagship product, Arikayce, has revolutionized the treatment of nontuberculous mycobacterial (NTM) lung disease, a debilitating condition that affects approximately 130,000 people worldwide. Arikayce has demonstrated remarkable efficacy, significantly improving patient outcomes and reducing the need for invasive surgery. Insmed is actively pursuing regulatory approvals in additional countries, expanding the reach of this life-changing therapy.


In addition to Arikayce, Insmed has a promising pipeline of investigational therapies targeting various respiratory diseases. The company is conducting late-stage clinical trials for brensocatib, a novel inhaled therapy for bronchiectasis, a chronic inflammatory lung condition. Early clinical data has shown promising results, suggesting the potential for brensocatib to transform the treatment paradigm for this underserved patient population.


Insmed's strong financial performance provides a solid foundation for future growth. The company has a healthy cash position and a robust revenue stream, which enables it to invest heavily in research and development. Insmed is also exploring strategic partnerships and acquisitions to accelerate its innovation pipeline and expand its commercial reach. With a dedicated management team and a commitment to patient care, Insmed is poised to continue its trajectory of success and make a meaningful difference in the lives of patients with respiratory diseases.


Insmed's Operating Efficiency: A Promising Trend

Insmed Incorporated, a biopharmaceutical company, has demonstrated a steady improvement in its operating efficiency over the past few years. This has been driven by several factors, including an increase in sales and marketing productivity, as well as cost-cutting initiatives. As a result, Insmed has been able to generate more revenue and profit with less expense.


One of the key drivers of Insmed's operating efficiency has been its increased sales and marketing productivity. The company has invested heavily in its sales force and marketing campaigns, which has led to a significant increase in product sales. Insmed has also been able to improve its margins by negotiating better deals with its suppliers and distributors.


In addition to increasing its sales and marketing productivity, Insmed has also implemented a number of cost-cutting initiatives. These initiatives have included reducing administrative expenses, streamlining operations, and outsourcing certain functions. As a result of these initiatives, Insmed has been able to significantly reduce its operating costs.


Insmed's improved operating efficiency is expected to continue in the years to come. The company has a number of new products in its pipeline, which are expected to drive sales growth. Insmed is also continuing to invest in its sales force and marketing campaigns, which is expected to further improve its sales and marketing productivity. As a result, Insmed is well-positioned to continue to improve its operating efficiency and generate strong financial results in the years to come.

Insmed Stock Risk Assessment

Insmed Incorporated (Insmed), a biopharmaceutical company, is publicly traded on the NASDAQ Stock Market under the ticker symbol INSM. Like all publicly traded companies, Insmed's stock carries certain risks that investors should consider before making an investment. These risks can be categorized into several key areas, including business risks, financial risks, and regulatory risks.


Business risks primarily relate to Insmed's operations and their exposure to external market factors. The company's revenue is heavily dependent on the sales of its lead product, Arikayce, which is used to treat nontuberculous mycobacterial (NTM) lung disease. Reliance on a single product can increase the company's vulnerability to changes in market dynamics, competition, or regulatory decisions. Additionally, Insmed faces challenges in expanding its product portfolio and diversifying its revenue streams.


Financial risks relate to Insmed's financial health and its ability to generate sustainable cash flow. The company has historically reported losses, and its profitability remains uncertain. Insmed's high research and development (R&D) expenses can further strain its finances, potentially affecting its ability to invest in future growth initiatives. Additionally, as a relatively small company, Insmed is exposed to risks of liquidity constraints, which could limit its access to capital and its ability to meet its financial obligations.


Regulatory risks stem from the company's exposure to government regulations and regulatory changes. The pharmaceutical industry is heavily regulated, and Insmed must comply with various regulations related to drug development, manufacturing, and marketing. Changes in regulatory policies or delays in regulatory approvals can significantly impact the company's ability to commercialize its products and generate revenue. Insmed also faces the risk of potential product liability claims or adverse events associated with its products.


References

  1. Athey S. 2019. The impact of machine learning on economics. In The Economics of Artificial Intelligence: An Agenda, ed. AK Agrawal, J Gans, A Goldfarb. Chicago: Univ. Chicago Press. In press
  2. Chernozhukov V, Newey W, Robins J. 2018c. Double/de-biased machine learning using regularized Riesz representers. arXiv:1802.08667 [stat.ML]
  3. Firth JR. 1957. A synopsis of linguistic theory 1930–1955. In Studies in Linguistic Analysis (Special Volume of the Philological Society), ed. JR Firth, pp. 1–32. Oxford, UK: Blackwell
  4. C. Claus and C. Boutilier. The dynamics of reinforcement learning in cooperative multiagent systems. In Proceedings of the Fifteenth National Conference on Artificial Intelligence and Tenth Innovative Applications of Artificial Intelligence Conference, AAAI 98, IAAI 98, July 26-30, 1998, Madison, Wisconsin, USA., pages 746–752, 1998.
  5. Brailsford, T.J. R.W. Faff (1996), "An evaluation of volatility forecasting techniques," Journal of Banking Finance, 20, 419–438.
  6. Hartford J, Lewis G, Taddy M. 2016. Counterfactual prediction with deep instrumental variables networks. arXiv:1612.09596 [stat.AP]
  7. R. Williams. Simple statistical gradient-following algorithms for connectionist reinforcement learning. Ma- chine learning, 8(3-4):229–256, 1992

Premium

  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

Login
This project is licensed under the license; additional terms may apply.